The next generation of anti-infective compounds effective against bacteria, viruses and fungi.
NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing its proprietary and patented Aganocide® compounds. Aganocides are novel, broad-spectrum, fast-acting, synthetic anti-infectives designed to mimic the body’s defense against infection. They are active against bacteria, fungi and viruses, and are being developed to treat and prevent a wide range of local, non-systemic infections with a low likelihood of developing bacterial resistance.
NeutroPhase®: Distinct from NovaBay’s Aganocides drug platform, NeutroPhase has been cleared by the U.S. Food and Drug Administration as a 510(k) medical device and is indicated as a skin and wound cleanser. NeutroPhase aims to help the more than 6 million patients in U.S. dealing with chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers. NeutroPhase is the only pure hypochlorous acid solution available today.
For additional information on NovaBay, visit: http://novabay.com/
NovaBay Pharmaceuticals, Inc.
5980 Horton Street, Suite 550
Emeryville, CA 94608
Office: (510) 899-8800
Fax: (510) 550-2771
NeutroPhase is a registered trademark of NovaBay Pharmaceuticals, Inc. (“NovaBay”)